Literature DB >> 7604009

Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries.

P P Sanna1, R A Williamson, A De Logu, F E Bloom, D R Burton.   

Abstract

Human monoclonal antibodies have considerable potential in the prophylaxis and treatment of viral disease. However, only a few such antibodies suitable for clinical use have been produced to date. We have previously shown that large panels of human recombinant monoclonal antibodies against a plethora of infectious agents, including herpes simplex virus types 1 and 2, can be established from phage display libraries. Here we demonstrate that facile cloning of recombinant Fab fragments against specific viral proteins in their native conformation can be accomplished by panning phage display libraries against viral glycoproteins "captured" from infected cell extracts by specific monoclonal antibodies immobilized on ELISA plates. We have tested this strategy by isolating six neutralizing recombinant antibodies specific for herpes simplex glycoprotein gD or gB, some of which are against conformationally sensitive epitopes. By using defined monoclonal antibodies for the antigen-capture step, this method can be used for the isolation of antibodies to specific regions and epitopes within the target viral protein. For instance, monoclonal antibodies to a nonneutralizing epitope can be used in the capture step to clone antibodies to neutralizing epitopes, or antibodies to a neutralizing epitope can be used to clone antibodies to a different neutralizing epitope. Furthermore, by using capturing antibodies to more immunodominant epitopes, one can direct the cloning to less immunogenic ones. This method should be of value in generating antibodies to be used both in the prophylaxis and treatment of viral infections and in the characterization of the mechanisms of antibody protective actions at the molecular level.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7604009      PMCID: PMC41533          DOI: 10.1073/pnas.92.14.6439

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance.

Authors:  C B Hwang; K L Ruffner; D M Coen
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

Review 2.  The role of antibody in herpes simplex virus infection in humans.

Authors:  S Kohl
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

Review 3.  Human monoclonal antibodies: achievement and potential.

Authors:  D R Burton
Journal:  Hosp Pract (Off Ed)       Date:  1992-08-15

4.  Different mechanisms of protection by monoclonal and polyclonal antibodies during the course of herpes simplex virus infection.

Authors:  A M Eis-Hübinger; K Mohr; K E Schneweis
Journal:  Intervirology       Date:  1991       Impact factor: 1.763

5.  Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use.

Authors:  R L Burke
Journal:  Rev Infect Dis       Date:  1991 Nov-Dec

6.  Humanized antibodies for antiviral therapy.

Authors:  M S Co; M Deschamps; R J Whitley; C Queen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

7.  Domains of herpes simplex virus I glycoprotein B that function in virus penetration, cell-to-cell spread, and cell fusion.

Authors:  D Navarro; P Paz; L Pereira
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

8.  Herpes simplex virus type 1 entry through a cascade of virus-cell interactions requires different roles of gD and gH in penetration.

Authors:  A O Fuller; W C Lee
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

9.  Identification and characterization of a novel herpes simplex virus glycoprotein, gK, involved in cell fusion.

Authors:  L Hutchinson; K Goldsmith; D Snoddy; H Ghosh; F L Graham; D C Johnson
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

10.  Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey.

Authors:  F Nugier; J N Colin; M Aymard; M Langlois
Journal:  J Med Virol       Date:  1992-01       Impact factor: 2.327

View more
  21 in total

1.  Construction of human naïve Fab library and characterization of anti-met Fab fragment generated from the library.

Authors:  Yongjun Jiao; Ping Zhao; Jin Zhu; Tessa Grabinski; Zhengqing Feng; Xiaohong Guan; R Scot Skinner; Milton D Gross; Rick V Hay; Hiroshi Tachibana; Brian Cao
Journal:  Mol Biotechnol       Date:  2005-09       Impact factor: 2.695

2.  Characterization of a type-common human recombinant monoclonal antibody to herpes simplex virus with high therapeutic potential.

Authors:  A De Logu; R A Williamson; R Rozenshteyn; F Ramiro-Ibañez; C D Simpson; D R Burton; P P Sanna
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

3.  Limitations of the semisynthetic library approach for obtaining human monoclonal autoantibodies to the thyrotropin receptor of Graves' disease.

Authors:  J H Van Der Heijden; T W De Bruin; K A Glaudemans; J De Kruif; J P Banga; T Logtenberg
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

4.  Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro.

Authors:  Z Mikloska; P P Sanna; A L Cunningham
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  Detection and typing of herpes simplex viruses by using recombinant immunoglobulin fragments produced in bacteria.

Authors:  P Cattani; G M Rossolini; S Cresti; R Santangelo; D R Burton; R A Williamson; P P Sanna; G Fadda
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

6.  A role for Src kinase in spontaneous epileptiform activity in the CA3 region of the hippocampus.

Authors:  P P Sanna; F Berton; M Cammalleri; M K Tallent; G R Siggins; F E Bloom; W Francesconi
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

7.  Production and characterization of a human recombinant monoclonal Fab fragment specific for influenza A viruses.

Authors:  Alessandra Desogus; Roberto Burioni; Angela Ingianni; Francesca Bugli; Raffaello Pompei; Giovanni Fadda
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

8.  A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo.

Authors:  John V Williams; Zhifeng Chen; Gabriella Cseke; David W Wright; Christopher J Keefer; Sharon J Tollefson; Ann Hessell; Amy Podsiad; Bryan E Shepherd; Pietro Paolo Sanna; Dennis R Burton; James E Crowe; R Anthony Williamson
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

Review 9.  Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Authors:  Kristian Daniel Ralph Roth; Esther Veronika Wenzel; Maximilian Ruschig; Stephan Steinke; Nora Langreder; Philip Alexander Heine; Kai-Thomas Schneider; Rico Ballmann; Viola Fühner; Philipp Kuhn; Thomas Schirrmann; André Frenzel; Stefan Dübel; Maren Schubert; Gustavo Marçal Schmidt Garcia Moreira; Federico Bertoglio; Giulio Russo; Michael Hust
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293

10.  Phage display on the base of filamentous bacteriophages: application for recombinant antibodies selection.

Authors:  N V Tikunova; V V Morozova
Journal:  Acta Naturae       Date:  2009-10       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.